Our current standard of administering an anti-GD2 moAb (dinutuximab) after autologous HSCT is limited in that the patient’s own NK cells must engage the antibody to eliminate the tumor, and risk engaging self-MHC on the tumor that could “turn off” the NK cell. Here, HLA-C is linked to neoplasm.